Form 4: Co-Diagnostics Director James Nelson Acquires 30,000 Shares of Common Stock

Director James Nelson acquired 30,000 shares of Co-Diagnostics common stock on May 23, 2024, through the vesting of restricted stock units.

Summary

• On May 23, 2024, James Nelson, a director of Co-Diagnostics, Inc., acquired 30,000 shares of common stock.
• This acquisition was a result of the vesting of restricted stock units (RSUs).
• The price per share for the acquisition was $0.00, indicating it was related to the vesting of previously granted equity.
• Following the transaction, Nelson directly owns 115,000 shares of Co-Diagnostics common stock.
• The RSUs were granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan and vest in installments every six months.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, and the acquisition of shares by a director is generally viewed as a slightly positive sign, but not significantly so.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and doesn't necessarily reflect broader industry trends.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates